Porat Shay, Dor Yuval
The Department of Cellular Biochemistry and Human Genetics, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.
Curr Diab Rep. 2007 Aug;7(4):304-8. doi: 10.1007/s11892-007-0049-8.
In both type 1 and type 2 diabetes, insufficient numbers of insulin-producing beta cells are a major cause of defective control of blood glucose and its complications. Accordingly, therapies that increase functional beta-cell mass may offer a cure for diabetes. Efforts to achieve this goal explore several directions. Based on the realization that beta cells are capable of significant proliferation throughout adult life, the enhanced proliferation of beta cells in vivo or in vitro is pursued as a strategy for regenerative medicine for diabetes. Alternatively, the conversion of differentiated cells such as hepatocytes into beta cells is being attempted using molecular insights into the transcriptional makeup of beta cells. Advances were also made in directing the differentiation of embryonic stem cells into beta cells. Although progress is encouraging, major gaps in our understanding of developmental biology of the pancreas and adult beta-cell dynamics remain to be closed before a therapeutic application is made possible.
在1型和2型糖尿病中,产生胰岛素的β细胞数量不足是血糖控制不佳及其并发症的主要原因。因此,增加功能性β细胞量的疗法可能为糖尿病提供治愈方法。为实现这一目标的努力探索了几个方向。基于β细胞在成年期能够大量增殖这一认识,β细胞在体内或体外的增殖增强被作为糖尿病再生医学的一种策略来进行研究。另外,利用对β细胞转录组成的分子认识,正在尝试将分化细胞(如肝细胞)转化为β细胞。在引导胚胎干细胞分化为β细胞方面也取得了进展。尽管进展令人鼓舞,但在实现治疗应用之前,我们对胰腺发育生物学和成年β细胞动态的理解仍存在重大差距有待填补。